Bronchiolitis obliterans (BO) is a late-onset noninfectious pulmonary complication of hematopoietic cell transplantation (HCT) and is typically associated with chronic graft-versus-host disease (GVHD). There are no effective therapies for BO and it often leads to significant morbidity and high mortality [1]. It is pathologically characterized by the presence of bronchiolar inflammation with submucosal and peribronchiolar fibrosis [2]. Imatinib, a specific tyrosine kinase inhibitor, has been shown to have antifibrogenic properties [3,4].
No takes yet. Share an insight, caveat, or question.
Majhail et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: